Investigation of the spread of an intramuscularly administered live gE-negative BHV1 marker vaccine among cattle on two farms;Onderzoek naar spreiding van een intramusculair toegediend levend ge-negatief BHV1 markervaccin op twee rundveebedrijven

Tijdschrift voor Diergeneeskunde

Volumn 123, Issue 4, 1998, Pages 109-111

  Van Der Poel, W H M ^a   Hage, J J ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Gezondheidsdienst voor Dieren   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E, BOVINE HERPESVIRUS TYPE 1; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CATTLE; CATTLE DISEASE; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION;

ANIMALS; ANTIBODIES, VIRAL; CATTLE; CATTLE DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPESVIRIDAE INFECTIONS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 0032519155     PISSN: 00407453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bosch JC, Frankena K, Franken P, Hage JJ, Jong MCM de, Kaashoek MJ, Maris-Veldhuis MA, Noordhuizen JPTM, Poel WHM van der, Verhoeff J, Weerdmeester K, Zimmer GM, and Oirschot JT van. Bovine herpesvirus 1 marker vaccines reduce the incidence of infections. Vaccine 1997a; (geaccepteerd voor publicatie).
2. Bosch JC. Bovine herpes 1 marker vaccines: tools for eradication? Doctoral Thesis, Utrecht 1997b.
3. Bosch JC, Kaashoek MJ, and Oirschot JT van. Inactivated marker vaccines are more efficacious in reducing field bovine herpesvirus 1 excretion after reactivation than a live marker vaccine. 1997c; Vaccine (geaccepteerd voor publicatie).
4. Hage JJ. Epidemiology of bovine herpesvirus type 1 infections, Doctoral Thesis, Utrecht 1997.
5. Kaashoek MJ, Moerman A, Madic J, Rijsewijk FAM, Quak J, Gielkens ALJ, and Oirschot JT van. A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus 1 is an efficacious and safe vaccine. Vaccine 1994; 12: 439-44.
6. Kaashoek MJ, Moerman A, Madic J, Weerdmeester K, Maris-Veldhuis M, Rijsewijk FAM, and Oirschot JT van. An inactivated vaccine based on a glycoprotein E-negative strain of bovine herpesvirus 1 induces protective immunity and allows serological differentiation. Vaccine 1995; 13: 342-6.
7. Kahrs RF. Bovine rhinotracheitis: a review and update. J Am Med Assoc 1977; 171: 1055-64.
8. Kramps JA, Magdalena J, Quak J, Weerdmeester K, Kaashoek MJ, Maris-Veldhuis MA, Rijsewijk FAM, Keil G, and Oirschot JT van. A simple, specific and highly sensitive blocking enzyme-linked assay for detection of antibodies to bovine herpesvirus type 1. J Clin Microbiol 1995; 32: 2175-81.
9. Roizman B, Desrosiers RC, Fleckenstein B, Lopez C, Minson AC, and Studdert MJ. The family herpesviridae: an update. Arch Virol 1992; 123: 425-49.
10. Strube W, Auer S, Abar B, Bergle RD, Block W, Heinen E, Kretzdorn D, Rodenbach C, and Schmeer N. Infectious bovine rhinotracheitis marker vaccines - chemically inactivated and live attenuated - for the improvement of BHV1 control programs: Evaluation of immunogenicity. Proc. XVIII world Buiatrics Congress, Bologna 1994: 761-4.
11. Poel WHM van der, Kramps JA, Quak J, Brand A, and Oirschot JT van. Persistence of bovine herpesvirus 1 (BHV1)-specific antibodies in cattle after intranasal vaccination with a live virus vaccine. Vet Rec 1995; 136: 347-8.
12. Drunen Littel- van den Hurk S van, Parker MD, Massie B, Hurk JV van den, Harland R, Babiuk LA, and Zamb TJ. Vaccine 1993; 11: 25-35.
13. Wiseman A, Msolla PM, Selman IE, Allan EM, Cornwell HJC, Pirie HM, and Imsay WS. Vet Rec 1978; 103: 391.